Table 1.

Cohort dosing characteristics

Cohort (Sample Size)Treatment Duration, wkStarting Roxadustat DosesCorrection and Maintenance Dosing Frequency
Low Wt, 40–60 kgMedium Wt, >60–90 kgHeavy Wt, >90–140 kg
A (n=24)1660 mg100 mg140 mgTIW to TIW
B (n=24)1660 mg100 mg140 mgTIW to BIWa
C (n=24)2450-mg fixed starting dose regardless of weightTIW to TIW
D (n=24)24100-mg fixed starting dose regardless of weightTIW to TIW
E (n=24)2470 mg100 mg150 mgBIW to QWb
F (n=25)2470-mg fixed starting dose regardless of weightTIW to BIW to QWc
  • Wt, weight; TIW, thrice weekly; BIW, twice weekly; QW, once weekly.

  • a Dose frequency reduction from TIW to BIW when hemoglobin response was reached.

  • b Dose frequency reduction from BIW to QW when hemoglobin response was reached.

  • c Dose frequency reduction from TIW to BIW when hemoglobin response was reached; additional dose frequency reduction from BIW to QW when hemoglobin and dose had been stable for 8 weeks.